- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT06326047
Tutkimus, jossa verrataan kuinka hyvin NN0519-0130 alentaa verensokeria ihmisillä, joilla on tyypin 2 diabetes
Kerran viikossa annettavan NNC0519-0130 turvallisuuden ja tehon tutkimus tyypin 2 diabetesta sairastavilla potilailla – annoksen löytämistutkimus
This study will look at how well a new medicine called NNC0519-0130 helps people with type 2 diabetes lower their blood sugar and body weight. The study will test up to 7 different doses of NNC0519-0130. Which treatment participant will get is decided by chance. Participants will take 1-3 injections once a week. The study medicine will be injected under skin with a thin needle in the stomach, thigh, or upper arm. The study will last for about 40 weeks.
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Vaihe 2
Yhteystiedot ja paikat
Opiskelupaikat
-
-
New South Wales
-
Campbelltown, New South Wales, Australia, 2560
- Campbelltown Hospital
-
Macquarie Park, New South Wales, Australia, 2109
- Macquarie University - Clinical Trials Unit
-
St Leonards, New South Wales, Australia, 2065
- Royal North Shore Hospital
-
Sydney, New South Wales, Australia, 2148
- Western Endocrine Blacktown
-
Sydney, New South Wales, Australia, 2148
- Roger Chih Yu Chen
-
Wollongong, New South Wales, Australia, 2500
- Illawarra Diabetes Service Clinical Trials & Research Unit
-
-
Queensland
-
Birtinya, Queensland, Australia, 4575
- University of Sunshine Coast - Vitality Village
-
Meadowbrook, Queensland, Australia, 4131
- Logan Hospital
-
-
South Australia
-
Oaklands Park, South Australia, Australia, 5046
- Southern Adelaide Diabetes & Endocrine Services
-
-
Victoria
-
Box Hill, Victoria, Australia, 3128
- Eastern Clinical Research Unit Box Hill
-
Camberwell, Victoria, Australia, 3124
- Emeritus Research Melbourne
-
Heidelberg Heights, Victoria, Australia, 3081
- Austin Health, Metabolic Disorders Centre
-
Parkville, Victoria, Australia, 3050
- The Royal Melbourne Hospital
-
Parkville, Victoria, Australia, 3050
- The Royal Melbourne Hospital - Diabetes & Endocrinology Department
-
-
Western Australia
-
Fremantle, Western Australia, Australia, 6160
- Fremantle Hospital
-
-
-
-
-
Seoul, Etelä -Korea, 05505
- Asan Medical Center
-
Seoul, Etelä -Korea, 01830
- Nowon Eulji Medical Center, Eulji University
-
Seoul, Etelä -Korea, 03181
- Kangbuk Samsung Hospital
-
Seoul, Etelä -Korea, 02841
- Korea University Anam Hospital
-
-
Gyeonggi-do
-
Seongnam-si, Gyeonggi-do, Etelä -Korea, 13620
- Seoul National University Bundang Hospital
-
-
-
-
Free State
-
Bloemfontein, Free State, Etelä-Afrikka, 9301
- Josha Research
-
-
Gauteng
-
Johannesburg, Gauteng, Etelä-Afrikka, 2013
- Wits Bara Clinical Trial Site
-
Midrand, Gauteng, Etelä-Afrikka, 1685
- Dr A Jacovides and Partners Inc
-
-
KwaZulu-Natal
-
Durban, KwaZulu-Natal, Etelä-Afrikka, 4450
- Dr Pillay's Rooms
-
eMkhomazi, KwaZulu-Natal, Etelä-Afrikka, 4170
- Dr T Padayachee
-
-
-
-
-
Bengaluru, Intia, 560054
- MS Ramaiah
-
New Delhi, Intia, 110001
- Lady Hardinge Medical College
-
-
Karnataka
-
Bangalore, Karnataka, Intia, 560092
- Life Care Hospital and Research Centre
-
-
Kerala
-
Kochi, Kerala, Intia, 682041
- Amrita Institute Of Medical Sciences & Research Centre
-
-
Madhya Pradesh
-
Indore, Madhya Pradesh, Intia, 452010
- TOTALL Diabetes Hormone Institute
-
-
Maharashtra
-
Mumbai, Maharashtra, Intia, 400012
- Seth GS Medical College & KEM Hospital
-
Pune, Maharashtra, Intia, 411021
- Chellaram Diabetes Institute
-
-
Rajasthan
-
Jaipur, Rajasthan, Intia, 302006
- Diabetes, Thyroid and Endocrine Centre
-
-
Tamil Nadu
-
Vellore, Tamil Nadu, Intia, 632004
- Christian Medical College Hospital, Vellore
-
-
Telangana
-
Hyderabad, Telangana, Intia, 500082
- Diabetes Research Center, Hyderabad
-
-
-
-
-
Chiba, Japani, 261-0004
- Tokuyama clinic_Diabetic internal medicine
-
Soka-shi, Saitama, Japani, 340-0015
- Soka Sugiura Internal Medicine Clinic
-
Tokyo, Japani, 104-0031
- Fukuwa Clinic
-
Tokyo, Japani, 103-0027
- Tokyo-Eki Center-building Clinic_Internal Medicine
-
Tokyo, Japani, 104-0031
- Fukuwa Clinic_Internal Medicine
-
-
-
-
-
Québec, Kanada, G1V 4T3
- Diex Recherche Quebec
-
-
British Columbia
-
Kelowna, British Columbia, Kanada, V1Y 1Z9
- OCT Research ULC (dba Okanagan Clinical Trials)
-
Richmond, British Columbia, Kanada, V6V 2L1
- OCT Research ULC (dba Okanagan Clinical Trials)
-
Victoria, British Columbia, Kanada, V8V 4A1
- Cook Street Medical Clinic
-
-
New Brunswick
-
Moncton, New Brunswick, Kanada, E1G 1A7
- G.A. Research Associates Ltd.
-
-
Nova Scotia
-
Halifax, Nova Scotia, Kanada, B3H 1V7
- Nova Scotia Hlth Halifax
-
-
Ontario
-
Barrie, Ontario, Kanada, L4N 7L3
- Centricity Research Barrie
-
Hamilton, Ontario, Kanada, L8L 5G8
- Wharton Medical Clinic Clinical Trials (Hamilton)
-
Sarnia, Ontario, Kanada, N7T 4X3
- London Road Diagnostic Clinic and Medical Centre
-
Toronto, Ontario, Kanada, M4G 3E8
- Centricity Research Toronto
-
Toronto, Ontario, Kanada, M9V 4B4
- Albion Finch Medical Centre
-
-
Quebec
-
Lévis, Quebec, Kanada, G6W 0M5
- Centricity Research Quebec City
-
Mirabel, Quebec, Kanada, J7J 2K8
- Centricity Research Mirabel
-
Montreal, Quebec, Kanada, H1Y 3H5
- Recherche GCP Research
-
Saint-Laurent, Quebec, Kanada, H4T 1Z9
- Centricity Research Ville St. Laurent VSL
-
-
-
-
California
-
Chula Vista, California, Yhdysvallat, 91911
- Velocity Clin Res-Chula Vista
-
Fresno, California, Yhdysvallat, 93720
- Valley Research
-
Inglewood, California, Yhdysvallat, 90301
- 310 Clinical Research
-
La Mesa, California, Yhdysvallat, 91942
- Velocity Clin Res San Diego
-
Lancaster, California, Yhdysvallat, 93534
- First Valley Med Grp Lancaster
-
Lomita, California, Yhdysvallat, 90717
- Torrance Clin Res Inst, Inc.
-
Los Alamitos, California, Yhdysvallat, 90720
- Pacific Clinical Studies
-
Los Angeles, California, Yhdysvallat, 90057
- Velocity Clinical Research Westlake
-
Montclair, California, Yhdysvallat, 91763
- Catalina Research Institute, LLC
-
San Diego, California, Yhdysvallat, 92123
- Artemis Insitute for Clin Res
-
Toluca Lake, California, Yhdysvallat, 91602
- Med Partners, Inc.
-
Torrance, California, Yhdysvallat, 90505
- UCLA Health Southbay Endocrine
-
Tustin, California, Yhdysvallat, 92780
- University Clin Investigators
-
Walnut Creek, California, Yhdysvallat, 94598
- Diablo Clinical Research, Inc.
-
-
Colorado
-
Aurora, Colorado, Yhdysvallat, 80045
- University of Colorado Hospital
-
-
Florida
-
Clearwater, Florida, Yhdysvallat, 33756
- Innovative Research of W Florida Inc.
-
Clearwater, Florida, Yhdysvallat, 33756
- Innovative Research of W FL
-
Miami, Florida, Yhdysvallat, 33183
- International Research Associates, LLC_Miami
-
-
Georgia
-
Columbus, Georgia, Yhdysvallat, 31904
- Centricity Research
-
-
Idaho
-
Blackfoot, Idaho, Yhdysvallat, 83221
- Elite Clinical Trials
-
-
Illinois
-
Peoria, Illinois, Yhdysvallat, 61603
- Methodist Medical Center of Illinois
-
-
Iowa
-
Iowa City, Iowa, Yhdysvallat, 52242
- University of Iowa
-
-
Maryland
-
Columbia, Maryland, Yhdysvallat, 21045
- Centennial Medical Group
-
Oxon Hill, Maryland, Yhdysvallat, 20745
- MD Medical Research
-
Rockville, Maryland, Yhdysvallat, 20852
- Endo And Metab Cons
-
-
Missouri
-
Springfield, Missouri, Yhdysvallat, 65807
- Clinvest Research
-
-
Montana
-
Butte, Montana, Yhdysvallat, 59701
- Mercury Str Med Grp, PLLC
-
-
Nebraska
-
Lincoln, Nebraska, Yhdysvallat, 68510
- Velocity Clinical Research Lincoln
-
-
Nevada
-
Las Vegas, Nevada, Yhdysvallat, 89148
- Palm Research Center Inc-Vegas
-
Las Vegas, Nevada, Yhdysvallat, 89109
- Excel Clinical Network
-
-
New York
-
Binghamton, New York, Yhdysvallat, 13905
- Velocity Clinical Research Binghamton
-
-
North Carolina
-
Greensboro, North Carolina, Yhdysvallat, 27408
- PharmQuest Life Sciences LLC
-
Wilmington, North Carolina, Yhdysvallat, 28401
- Accellacare Wilmington
-
-
Ohio
-
Canton, Ohio, Yhdysvallat, 44718
- Diab & Endo Assoc of Stark Co
-
Cincinnati, Ohio, Yhdysvallat, 45242
- Velocity Clin Res_Cincinnati
-
Cincinnati, Ohio, Yhdysvallat, 45246
- Velocity Clinical Research Springdale
-
Dayton, Ohio, Yhdysvallat, 45439
- Providence Health Partners Ctr
-
Maumee, Ohio, Yhdysvallat, 43537
- Advanced Med Res Maumee
-
-
Oregon
-
Grants Pass, Oregon, Yhdysvallat, 97527
- Velocity Clin Res Grants Pass
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Yhdysvallat, 19114
- Tristar Clin Investigations, PC
-
Pittsburgh, Pennsylvania, Yhdysvallat, 15243
- Preferred Primary Care Physicians Inc.
-
Uniontown, Pennsylvania, Yhdysvallat, 15401
- Preferred Primary Care Physicians, Inc.
-
-
Texas
-
Abilene, Texas, Yhdysvallat, 79606
- Velocity Clinical Research Abilene
-
Austin, Texas, Yhdysvallat, 78759
- Velocity Clin Res Austin
-
Dallas, Texas, Yhdysvallat, 75390
- UT Southwestern Med Center
-
Dallas, Texas, Yhdysvallat, 75230
- Velocity Clinical Res-Dallas
-
Dallas, Texas, Yhdysvallat, 75230
- Zenos Clinical research
-
Forney, Texas, Yhdysvallat, 75126
- Care United Research, LLC
-
Houston, Texas, Yhdysvallat, 77004
- Endocrine Associates Houston
-
Houston, Texas, Yhdysvallat, 77043
- Biopharma Informatic_Houston
-
Irving, Texas, Yhdysvallat, 75039
- Tekton Research
-
Lewisville, Texas, Yhdysvallat, 75057
- Epic Clinical Research
-
Shavano Park, Texas, Yhdysvallat, 78231
- Consano Clinical Research, LLC
-
-
Virginia
-
Burke, Virginia, Yhdysvallat, 22015
- Burke Internal Medicine & Research
-
Newport News, Virginia, Yhdysvallat, 23606
- TPMG Clinical Research
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Female of non-childbearing potential, or male.
- For United States (US) only: Female of childbearing potential using highly effective non-systemic methods of contraception with low user-dependency and willingness to continue using it through-out the study or male.
- Age 18-75 years (both inclusive) at the time of signing the informed consent.
- Diagnosed with type 2 diabetes mellitus greater than or equal 180 days before screening.
- Stable daily dose(s) more than or equal 90 days before screening of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator: metformin with or without sodium-glucose co-transporter 2 (SGLT2) inhibitor.
- Glycated haemoglobin (HbA1c) of 7.5-10.0% (58-86 millimoles per moles (mmol/mol)) (both inclusive) as assessed by central laboratory at screening.
- Body mass index (BMI) greater than or equal 23.0 kilograms per meter square (kg/m^2).
Exclusion Criteria:
- Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.
- Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
- Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire question.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Nelinkertaistaa
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Dosing scheme A (NNC0519-0130)
Participants will receive NNC0519-0130 at 3 dose levels once weekly (QW) as subcutaneous (s.c.) injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
Placebo Comparator: Dosing scheme A (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
Kokeellinen: Dosing scheme B (NNC0519-0130)
Participants will receive NNC0519-0130 at 3 dose levels once weekly (QW) as s.c. injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
Placebo Comparator: Dosing scheme B (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
Kokeellinen: Dosing scheme C (NNC0519-0130)
Participants will receive NNC0519-0130 at 5 dose levels once weekly as s.c. injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
Placebo Comparator: Dosing scheme C (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
Kokeellinen: Dosing scheme D (NNC0519-0130)
Participants will receive NNC0519-0130 at 5 dose levels once weekly as s.c. injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
Placebo Comparator: Dosing scheme D (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
Kokeellinen: Dosing scheme E (NNC0519-0130)
Participants will receive NNC0519-0130 at 7 dose levels once weekly as s.c. injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
Placebo Comparator: Dosing scheme E (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
Active Comparator: Dosing scheme F (tirzepatide)
Participants will receive tirzepatide at 6 dose levels once weekly as s.c. injection in dose escalating manner. |
Trizepatide will be administered subcutaneously. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Change in Glycated haemoglobin (HbA1c)
Aikaikkuna: From baseline (week 0) to 12 weeks on a given maintenance dose
|
Measured as percentage point (%-point) |
From baseline (week 0) to 12 weeks on a given maintenance dose
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Change in Glycated haemoglobin (HbA1c)
Aikaikkuna: From baseline (week 0) to end of treatment (week 36)
|
Measured as percentage point (%-point) |
From baseline (week 0) to end of treatment (week 36)
|
|
Relative change in body weight
Aikaikkuna: From baseline (week 0) to end of treatment (week 36)
|
Measured as percentage (%) |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in body weight
Aikaikkuna: From baseline (week 0) to end of treatment (week 36)
|
Measured as kilograms (kg) |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in fasting plasma glucose (FPG)
Aikaikkuna: From baseline (week 0) to 12 weeks on a given maintenance dose
|
Measured as millimoles per liter (mmol/L) |
From baseline (week 0) to 12 weeks on a given maintenance dose
|
|
Continuous glucose monitoring (CGM): Change in time in range (TIR) 3.9-10.0 millimoles per liter (mmol/L) (70-180 milligrams per deciliter (mg/dL))
Aikaikkuna: From baseline (week -2 to week 0) to week 22-24 and week 34-36, respectively
|
Measured as percentage point (%-point) |
From baseline (week -2 to week 0) to week 22-24 and week 34-36, respectively
|
|
Change in waist circumference
Aikaikkuna: From baseline (week 0) to end of treatment (week 36)
|
Measured as centimeter (cm) |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in systolic blood pressure (SBP)
Aikaikkuna: From baseline (week 0) to end of treatment (week 36)
|
Measured as millimeters of mercury (mmHg) |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in high sensitivity C-Reactive Protein (hsCRP)
Aikaikkuna: From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in total cholesterol
Aikaikkuna: From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in high-density lipoprotein (HDL) cholesterol
Aikaikkuna: From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in low-density lipoprotein (LDL) cholesterol
Aikaikkuna: From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in triglycerides
Aikaikkuna: From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Number of adverse events
Aikaikkuna: From baseline (week 0) to end of study (week 40)
|
Measured as number of events |
From baseline (week 0) to end of study (week 40)
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Opintojohtaja: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- NN9541-4945
- U1111-1291-9196 (Muu tunniste: World Health Organization (WHO))
- jRCT2031230704 (Rekisterin tunniste: JRCT)
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .